Geeraerts Xenia - Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel;Laboratory of Myeloid Cell Immunology, VIB

基本信息

浏览量：9

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 20 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Intratumoral Administration of the Immunologic Adjuvant AS01B in Combination with Autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ Myeloid Dendritic Cells Plus Ipilimumab and Intravenous Nivolumab in Patients with Refractory Advanced Melanoma

Jens Tijtgat,Xenia Geeraerts,Anais Boisson,Latoya Stevens,Manon Vounckx,Iris Dirven,Julia Katharina Schwarze,Steven Raeymaeckers,Ramses Forsyth,Ivan Van Riet,Sandra Tuyaerts,Karen Willard-Gallo,Bart Neyns

JOURNAL FOR IMMUNOTHERAPY OF CANCERno. 1 (2024)

引用0浏览0WOS引用

Intracranial Administration of Anti-Pd-1 and Anti-Ctla-4 Immune Checkpoint-Blocking Monoclonal Antibodies in Patients with Recurrent High-Grade Glioma

Johnny Duerinck, Louise Lescrauwaet, Iris Dirven, Jacomi Del'haye,Latoya Stevens,Xenia Geeraerts,Freya Vaeyens,Wietse Geens, Stefanie Brock,Anne-Marie Vanbinst,Hendrik Everaert,Ben Caljon,Michael Bruneau,Laetitia Lebrun,Isabelle Salmon, Marc Kockx, Sandra Tuyaerts, Bart Neyns

NEURO-ONCOLOGY (2024)

引用0浏览0WOS引用

441O A Phase I Clinical Trial on the Intracranial Administration of Autologous CD1c(BDCA-1)+ /CD141(BDCA-3)+ Myeloid Dendritic Cells (mydc) in Combination with Ipilimumab (IPI) and Nivolumab (NIVO) in Patients with Recurrent High-Grade Glioma (Rhgg)

B. Neyns,I. Dirven, L. Lescrauwaet, M. Cammaert,W. Geens,X. Geeraerts, L. Stevens, S. Brock, M. Kockx, H. Everaert, A-M. Van Binst,S. Tuyaerts,J. Duerinck

Annals of Oncology (2024)

引用0浏览0引用

A Phase I Trial on the Intra- and Post-Operative Intracranial Administration of Ipilimumab and Nivolumab in Patients with Recurrent High-Grade Glioma

Bart Neyns, Iris Dirven, Louise Lescrauwaet, Jacomi Del'haye,Wietse Geens,Xenia Geeraerts,Latoya Stevens, Stefanie Brock,Mark Kockx,Laura Seynaeve,Hendrik Everaert,Anne-Marie Vanbinst, Sandra Tuyaerts,Johnny Duerinck

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

1086P Intratumoral (IT) Administration of Autologous CD1c(BDCA-1)+/CD141(BDCA-3)+myeloid Dendritic Cells (mydc) with the Immunologic Adjuvant AS01B Plus Ipilimumab (IPI) and IV Nivolumab (NIVO) in Patients with Refractory Advanced Melanoma: A Phase Ib Clinical Trial

M. Vounckx,I. Dirven, J.I. Kessels, L. Stevens,X. Geeraerts,A. Boisson, I. Van Riet, R. Forsyth,K. Willard-Gallo,S. Tuyaerts, B. Neyns

Annals of Oncology (2024)

引用0浏览0引用

P06.18.b overview of the glitipni trial - local administration of immune checkpoint inhibition and/or dendritic cells following resection of recurrent glioblastoma

Johnny Duerinck,Jens Tijtgat,Iris Dirven,Wietse Geens, Susannah Brock,Alex Michotte,X Geeraerts,Laura E. Stevens, S Thuyaerts,Hendrik Everaert, Anne‐Marie Vanbinst,Michaël Bruneau,Anne Rogiers,Bart Neyns

Neuro-Oncologyno. Supplement_2 (2023): ii49-ii50

引用0浏览0引用

694 A randomized phase II clinical trial of SBRT and pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c(BDCA-1)+/CD141(BDCA-3)+ myeloid dendritic cells in solid tumors

Bart Neyns,Bart Ilsen,Jens Tijtgat,Frederik Vandenbroucke,Inès Dufait,Sandra Tuyaerts,Ivan Van Riet,Xenia Geeraerts,Latoya Stevens,Manon Vounckx,Iris Dirven, Steven Raemaeckers,Selma Ben Mustapha, Jens Van Loon,Lore Decoster,Mark De Ridder

Journal for ImmunoTherapy of Cancerno. Suppl 1 (2023)

引用0浏览0引用

Current "state of the art" on dendritic cell-based cancer vaccines in melanoma

Julia Katharina Schwarze,Xenia Geeraerts,Sandra Tuyaerts,Bart Neyns

Curr Opin Oncol（2023）

引用3浏览0WOS引用

CTIM-12. A PHASE I CLINICAL TRIAL ON THE INTRACRANIAL ADMINISTRATION OF INCREASING DOSES OF IPILIMUMAB PLUS FIXED DOSE NIVOLUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGB)

Wietse Geens,Julia Katharina Schwarze,Jens Tijtgat,Louise Lescrauwaet,Sandra Tuyaerts,Xenia Geeraerts,Latoya Stevens, Anne-Marie Vanbinst,Hendrik Everaert,Michael Bruneau,Johnny Duerinck,Bart Neyns

NEURO-ONCOLOGY（2022）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn